Pediatric Sjogren Syndrome Medication

  • Author: Eyal Muscal, MD; Chief Editor: Lawrence K Jung, MD   more...
 
Updated: Aug 25, 2011
 

Medication Summary

Primary Sjögren syndrome usually follows a benign course in adult patients, and conservative management is indicated. Therapeutic approaches may include increasing lubrication with artificial tears, stimulating salivary flow with sugar-free gum or lozenges, and using vaginal lubricants. Saliva substitutes (eg, carboxymethylcellulose) are not usually effective. Cholinergic agonists have been shown to help increase salivary secretion and are approved by the US Food and Drug Administration (FDA) for this use. The treatment of secondary Sjögren syndrome is determined by the severity of the overlapping autoimmune disorder and may include the use of additional agents, such as methotrexate, cyclophosphamide, rituximab, and mycophenolate.

Next

Cholinergic agonists

Class Summary

These agents stimulate salivary secretion.

View full drug information

Pilocarpine (Salagen)

 

Pilocarpine is a muscarinic M3 receptor agonist.

View full drug information

Cevimeline (Evoxac)

 

Cevimeline is a muscarinic M3 agonist. It has 40-fold less binding affinity to M2 receptors and therefore has the theoretical benefit of causing less stimulation of cardiac tissues. This agent has a longer duration of action than pilocarpine.

Previous
Next

Immunosuppressive agents

Class Summary

These agents are used to treat extraglandular disease (ie, interstitial pneumonitis, glomerulonephritis, polyarthritis, vasculitis, pseudolymphoma, neurologic manifestations).

View full drug information

Prednisone

 

Prednisone is a corticosteroid with salt-retention properties used for its potent anti-inflammatory effects.

Previous
Next

Nonsteroidal Anti-Inflammatory Drugs

Class Summary

The use of NSAIDs in Sjögren syndrome is similar to agents used for juvenile arthritis. These agents may be used to treat polyarthritis associated with Sjögren syndrome.

View full drug information

Ibuprofen (Motrin, Advil, Caldolor)

 

Ibuprofen is the drug of choice for patients with mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. It also has anti-inflammatory and antipyretic properties. Ibuprofen is available in 200-, 400-, 600-, and 800-mg doses.

View full drug information

Naproxen (Aleve, Naprosyn, Naprelan)

 

Naproxen is used for the relief of mild to moderate pain. It inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Previous
Next

Disease-Modifying Antirheumatic Drugs

Class Summary

These agents are used for polyarthritis not controlled with nonsteroidal anti-inflammatory drugs (NSAIDs). Methotrexate has been shown to be effective in managing polyarthritis. Other DMARDs, such as hydroxychloroquine, may be synergistic when coadministered with methotrexate.

View full drug information

Methotrexate (Trexall, Rheumatrex)

 

Methotrexate has an unknown mechanism of action in the treatment of inflammatory reactions (although it may involve adenosine receptors). The drug, which may affect immune function, ameliorates symptoms of inflammation (eg, pain, swelling, stiffness). Adjust the dose gradually to attain a satisfactory response.

Previous
Next

Antimalarial Agents

Class Summary

These agents may inhibit chemotaxis of eosinophils and the locomotion of neutrophils and may impair complement-dependent antigen-antibody reactions.

View full drug information

Hydroxychloroquine sulfate (Plaquenil)

 

The mechanism of action for this drug is unclear; in the treatment of inflammatory arthritis, the mechanism of action is unknown. Hydroxychloroquine sulfate may inhibit chemotaxis of eosinophils and the locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions.

Previous
 
Contributor Information and Disclosures
Author

Eyal Muscal, MD  Assistant Professor, Section of Pediatric Rheumatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital

Eyal Muscal, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Rheumatology, and Clinical Immunology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Marietta Morales DeGuzman, MD  Assistant Professor, Department of Pediatrics, Baylor College of Medicine; Consulting Staff, Section of Pediatric Rheumatology, Department of Pediatrics, Texas Children's Hospital, Ben Taub General Hospital

Marietta Morales DeGuzman, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Rheumatology, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Lawrence K Jung, MD  Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Catherine M Flaitz, DDS, MS  Professor of Oral and Maxillofacial Pathology and Pediatric Dentistry, Department of Diagnostic Sciences, University of Texas Health Sciences Center at Houston, Dental Branch

Catherine M Flaitz, DDS, MS is a member of the following medical societies: American Academy of Oral and Maxillofacial Pathology, American Academy of Oral Medicine, American Academy of Pediatric Dentistry, American Dental Association, International Association for Dental Research, and International Association of Oral Pathologists

Disclosure: Trimira, LLC Clinical contract for study Co-investigator on clinical grant; Trimira, LLC Honoraria Speaking and teaching; GC America Clinical contract for study Co-investigator on clinical grant

Specialty Editor Board

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David D Sherry, MD  Director, Clinical Rheumatology, Attending Physician, Pain Management, The Children's Hospital of Philadelphia; Professor of Pediatrics, University of Pennsylvania School of Medicine

David D Sherry, MD is a member of the following medical societies: American College of Rheumatology and American Pain Society

Disclosure: Nothing to disclose.

Chief Editor

Lawrence K Jung, MD  Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

References

  1. Fox RI. Sjogren's syndrome. Lancet. Jul 23-29 2005;366(9482):321-31. [Medline].

  2. Jonsson R, Haga H-J, Gordon TP. Sjogren's syndrome. In: Koopman's Textbook of Arthritis and Allied Health Conditions. 14th ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2001:1736-59.

  3. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, et al. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum. Mar 2004;50(3):882-91. [Medline].

  4. Cassidy JT, Petty RE, Laxer RM. Overlap syndromes. In: Textbook of Pediatric Rheumatology. 5th ed. 2005:486-89.

  5. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis. Mar 2005;64(3):347-54. [Medline]. [Full Text].

  6. Ramos-Casals M, Font J. Primary Sjogren's syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford). Nov 2005;44(11):1354-67. [Medline].

  7. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. Jun 28 2004;164(12):1275-84. [Medline].

  8. Civilibal M, Canpolat N, Yurt A, et al. A child with primary Sjogren syndrome and a review of the literature. Clin Pediatr (Phila). Oct 2007;46(8):738-42. [Medline].

  9. Cimaz R, Casadei A, Rose C, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Paediatr. 2003;162 (10):661-5. [Medline].

  10. Anaya JM, Ogawa N, Talal N. Sjogren's syndrome in childhood. J Rheumatol. Jun 1995;22(6):1152-8. [Medline].

  11. Nakamura Y, Wakamatsu E, Matsumoto I, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjogren syndrome. Ann Rheum Dis. Jan 2008;67(1):136-7. [Medline].

  12. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int. Jan 2008;28(3):205-15. [Medline].

  13. Reveille JD, Arnett FC. The immunogenetics of Sjogren's syndrome. Rheum Dis Clin North Am. Aug 1992;18(3):539-50. [Medline].

  14. Singer NG, Tomanova-Soltys I, Lowe R. Sjogren's syndrome in childhood. Curr Rheumatol Rep. Apr 2008;10(2):147-55. [Medline].

  15. DeGuzman M, Fishman MA, Lewis RA, et al. Chronic neurologic disease with visual, gait and bladder problems in a male teenager. J Pediatr. 1998;132:742-47. [Medline].

  16. Kobayashi I, Furuta H, Tame A, et al. Complications of childhood Sjogren syndrome. Eur J Pediatr. Oct 1996;155(10):890-4. [Medline].

  17. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). Jul 2008;87(4):210-9. [Medline].

  18. Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjogren's syndrome in children and adolescents: are proposed diagnostic criteria applicable?. J Rheumatol. Nov 2005;32(11):2225-32. [Medline].

  19. Pessler F, Emery H, Dai L, Wu YM, Monash B, Cron RQ, et al. The spectrum of renal tubular acidosis in paediatric Sjögren syndrome. Rheumatology (Oxford). Jan 2006;45(1):85-91. [Medline].

  20. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. Jun 2002;61(6):554-8. [Medline]. [Full Text].

  21. Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren's syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. May-Jun 1999;17(3):381-6. [Medline].

  22. Rigante D, Inzitari R, Carone M, et al. Correspondence between clinical improvement and proteomic changes of the salivary peptide complex in a child with primary Sjogren syndrome. Rheumatol Int. Jun 2008;28(8):801-6. [Medline].

  23. Stiller M, Golder W, Döring E, Kliem K. Diagnostic value of sialography with both the conventional and digital subtraction techniques in children with primary and secondary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Nov 1999;88(5):620-7. [Medline].

  24. Fox PC, Brennan M, Pillemer S, Radfar L, Yamano S, Baum BJ. Sjogren's syndrome: a model for dental care in the 21st century. J Am Dent Assoc. Jun 1998;129(6):719-28. [Medline].

  25. van der Reijden WA, Vissink A, Veerman EC, Amerongen AV. Treatment of oral dryness related complaints (xerostomia) in Sjogren's syndrome. Ann Rheum Dis. Aug 1999;58(8):465-74. [Medline].

  26. Suzuki K, Matsumoto M, Nakashima M, Takada K, Nakanishi T, Okada M, et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology. May 2005;74(2):100-5. [Medline].

 
Previous
Next
 
Lower facial appearance of a 14-year-old adolescent girl with Sjogren syndrome. She exhibits both parotid and submandibular gland enlargement and chapped lips.
Intraoral view of a 14-year-old adolescent girl with Sjogren syndrome. Hyposalivation results in erythema of the mucosa, gingivitis, decalcification or white spot lesions of the teeth at the cervical margin, and dental caries with extensive restorations of the posterior teeth.
Erythema of the labial mucosa with enlargement of the minor salivary glands and superficial mucoceles.
The dorsal surface of the tongue demonstrates generalized atrophy of the filiform papillae, mild fissuring, and median rhomboid glossitis.
A 14-year-old adolescent girl with Sjogren syndrome with painful unilateral swelling of the knee and hyperpigmentation of the overlying skin.
The dorsal tongue demonstrates hyperplastic candidiasis with focal erosions and a brown hairy tongue. Ulcerated fissures are observed on the corners of the mouth that represent angular cheilitis.
Biopsy of the minor salivary glands of the lower lip may be useful in the diagnosis of Sjögren syndrome. A 1.5- to 2-cm incision of normal-appearing mucosa allows for the harvesting of 5 or more salivary gland lobules.
Low-power photomicrograph of a minor salivary gland lobule showing multiple lymphocytic foci that are replacing the acinar structures (hematoxylin-eosin, 40 X).
Intermediate-power photomicrograph demonstrating a chronic inflammatory aggregate of more than 50 lymphocytes and plasma cells with a periductal pattern. The inflammatory focus is adjacent to normal appearing acini (hematoxylin-eosin, 200 X).
High-power photomicrograph of the chronic inflammatory aggregate consists of lymphocytes and plasma cells around a ductal structure (hematoxylin-eosin, 400 X).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.